Details of the Drug

General Information of Drug (ID: DMOL54H)

Drug Name
Clopidogrel
Synonyms
clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [1]
Atherosclerosis BD40 Approved [1]
Myocardial infarction BA41-BA43 Approved [1]
Thrombosis DB61-GB90 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Intracranial embolism 8B22.1 Investigative [1]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 321.8
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 23.65 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.06 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.3168 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.01 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.05078 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Cardiovascular disorders rs4244285 CYP2C19 OTFMJYYE [7]
Chemical Identifiers
Formula
C16H16ClNO2S
IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
Canonical SMILES
COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
InChI
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChIKey
GKTWGGQPFAXNFI-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
60606
ChEBI ID
CHEBI:37941
CAS Number
113665-84-2
DrugBank ID
DB00758
TTD ID
D0N0TZ
VARIDT ID
DR00245
INTEDE ID
DR0355
ACDINA ID
D00142
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2Y purinoceptor 12 (P2RY12) TTZ1DT0 P2Y12_HUMAN Antagonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [14]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [9]
Brain-derived neurotrophic factor (BDNF) OTLGH7EW BDNF_HUMAN Protein Interaction/Cellular Processes [15]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Gene/Protein Processing [16]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Gene/Protein Processing [16]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [17]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [18]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Biotransformations [19]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [18]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [20]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clopidogrel
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Clopidogrel and Apixaban. Thrombosis [DB61-GB90] [21]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Clopidogrel and Brilinta. Thrombosis [DB61-GB90] [21]
Coadministration of a Drug Treating the Disease Different from Clopidogrel (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Major Decreased metabolism of Clopidogrel caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [22]
Pioglitazone DMKJ485 Major Decreased metabolism of Clopidogrel caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [23]
Oliceridine DM6MDCF Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Oliceridine. Acute pain [MG31] [24]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Clopidogrel caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Rabeprazole DMMZXIW Major Decreased metabolism of Clopidogrel caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [26]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Clopidogrel caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Pexidartinib DMS2J0Z Moderate Decreased metabolism of Clopidogrel caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [26]
Loperamide DMOJZQ9 Major Decreased metabolism of Clopidogrel caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [27]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Clopidogrel caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Tucatinib DMBESUA Major Decreased metabolism of Clopidogrel caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Letrozole DMH07Y3 Moderate Decreased metabolism of Clopidogrel caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Atorvastatin DMF28YC Moderate Increased plasma concentrations of Clopidogrel and Atorvastatin due to competitive inhibition of the same metabolic pathway. Cardiovascular disease [BA00-BE2Z] [25]
Dihydrocodeine DMB0FWL Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Dihydrocodeine. Chronic pain [MG30] [30]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Clopidogrel and Levomilnacipran. Chronic pain [MG30] [31]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Clopidogrel and Anisindione. Coagulation defect [3B10] [32]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Clopidogrel and Regorafenib. Colorectal cancer [2B91] [21]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Clopidogrel and Intedanib. Colorectal cancer [2B91] [33]
Alfentanil DMVO0UB Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Alfentanil. Corneal disease [9A76-9A78] [24]
Remifentanil DMZTXCH Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Remifentanil. Corneal disease [9A76-9A78] [24]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Clopidogrel and Ardeparin. Coronary thrombosis [BA43] [34]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Clopidogrel caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [26]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Clopidogrel and Danaparoid. Deep vein thrombosis [BD71] [34]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Clopidogrel and Rivaroxaban. Deep vein thrombosis [BD71] [35]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Clopidogrel and Sertraline. Depression [6A70-6A7Z] [31]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Clopidogrel and Vilazodone. Depression [6A70-6A7Z] [31]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Clopidogrel and Vortioxetine. Depression [6A70-6A7Z] [31]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Clopidogrel and Milnacipran. Depression [6A70-6A7Z] [31]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Clopidogrel and Escitalopram. Depression [6A70-6A7Z] [31]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Clopidogrel and Desvenlafaxine. Depression [6A70-6A7Z] [31]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Clopidogrel and Clomipramine. Depression [6A70-6A7Z] [31]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Clopidogrel and Heme. Discovery agent [N.A.] [36]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Clopidogrel and Apigenin. Discovery agent [N.A.] [37]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Clopidogrel and PMID28870136-Compound-49. Discovery agent [N.A.] [22]
Felbamate DM1V5ZS Moderate Decreased metabolism of Clopidogrel caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Clopidogrel caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DM8KLU9 Moderate Decreased metabolism of Clopidogrel caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Fosphenytoin DMOX3LB Minor Decreased metabolism of Clopidogrel caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Brivaracetam DMSEPK8 Moderate Decreased metabolism of Clopidogrel caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Clopidogrel caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Clopidogrel and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [39]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Clopidogrel caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [26]
Dexlansoprazole DM1DBV5 Minor Increased plasma concentrations of Clopidogrel and Dexlansoprazole due to competitive inhibition of the same metabolic pathway. Gastro-oesophageal reflux disease [DA22] [40]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Clopidogrel and Avapritinib. Gastrointestinal stromal tumour [2B5B] [21]
Rifampin DMA8J1G Moderate Increased metabolism of Clopidogrel caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [30]
Cobicistat DM6L4H2 Major Decreased metabolism of Clopidogrel caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Clopidogrel and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [41]
Etravirine DMGV8QU Moderate Decreased metabolism of Clopidogrel caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Fluvastatin DM4MDJY Minor Decreased metabolism of Clopidogrel caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [38]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Clopidogrel caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [26]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Clopidogrel caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [42]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Clopidogrel caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [30]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Clopidogrel and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [43]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Clopidogrel and Acalabrutinib. Mature B-cell lymphoma [2A85] [44]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Clopidogrel and Ibrutinib. Mature B-cell lymphoma [2A85] [24]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Clopidogrel and Ponatinib. Mature B-cell lymphoma [2A85] [45]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Clopidogrel and Panobinostat. Multiple myeloma [2A83] [30]
Ozanimod DMT6AM2 Major Decreased metabolism of Clopidogrel caused by Ozanimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [30]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Clopidogrel caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [26]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Clopidogrel and Dasatinib. Myeloproliferative neoplasm [2A20] [46]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Clopidogrel and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [47]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Clopidogrel and Prasugrel. Myocardial infarction [BA41-BA43] [21]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Clopidogrel and Tirofiban. Myocardial infarction [BA41-BA43] [48]
Bupropion DM5PCS7 Moderate Decreased metabolism of Clopidogrel caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [30]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Clopidogrel and Sibutramine. Obesity [5B80-5B81] [31]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Clopidogrel and Dexfenfluramine. Obesity [5B80-5B81] [31]
Levomethadyl Acetate DM06HG5 Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Clopidogrel and Nepafenac. Osteoarthritis [FA00-FA05] [39]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Clopidogrel and MK-4827. Ovarian cancer [2C73] [21]
Oxymorphone DM65AGJ Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Oxymorphone. Pain [MG30-MG3Z] [24]
Levorphanol DMGS80V Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Levorphanol. Pain [MG30-MG3Z] [24]
Dezocine DMJDB0Y Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Dezocine. Pain [MG30-MG3Z] [24]
Nalbuphine DMOSQGU Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Nalbuphine. Pain [MG30-MG3Z] [24]
Buprenorphine DMPRI8G Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Buprenorphine. Pain [MG30-MG3Z] [24]
Hydrocodone DMQ2JO5 Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Hydrocodone. Pain [MG30-MG3Z] [24]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Clopidogrel and Bromfenac. Postoperative inflammation [1A00-CA43] [39]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Clopidogrel caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [26]
Enzalutamide DMGL19D Moderate Decreased metabolism of Clopidogrel caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [49]
Selexipag DMAHSU0 Moderate Decreased metabolism of Clopidogrel caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [30]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Clopidogrel and Epoprostenol. Pulmonary hypertension [BB01] [50]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Clopidogrel and Iloprost. Pulmonary hypertension [BB01] [50]
Fentanyl DM8WAHT Moderate Altered absorption of Clopidogrel due to GI dynamics variation caused by Fentanyl. Sensation disturbance [MB40] [24]
Armodafinil DMGB035 Moderate Decreased metabolism of Clopidogrel caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Clopidogrel and Curcumin. Solid tumour/cancer [2A00-2F9Z] [51]
Taxol DMUOT9V Moderate Decreased metabolism of Clopidogrel caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [52]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Clopidogrel and Caplacizumab. Thrombocytopenia [3B64] [30]
Tolbutamide DM02AWV Minor Decreased metabolism of Clopidogrel caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [38]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Clopidogrel and Betrixaban. Venous thromboembolism [BD72] [53]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Clopidogrel caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [54]
⏷ Show the Full List of 88 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Caprylic acid E00017 379 Emulsifying agent; Flavoring agent; Surfactant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Zinc stearate E00209 11178 lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Trihydroxystearin E00317 25100 Emollient; Emulsifying agent; Solvent; Surfactant; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clopidogrel 75 mg tablet 75 mg Oral Tablet Oral
Clopidogrel 300 mg tablet 300 mg Oral Tablet Oral
Clopidogrel Bisulfate 75mg/300mg tablet 75mg/300mg Tablet Oral
Clopidogrel Bisulfate 75mg tablet 75mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Clopidogrel FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7150).
3 Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
8 P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
9 Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
12 Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
13 Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
14 Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
15 Differential effect of clopidogrel and aspirin on the release of BDNF from platelets. J Neuroimmunol. 2011 Sep 15;238(1-2):104-6. doi: 10.1016/j.jneuroim.2011.06.015. Epub 2011 Jul 31.
16 Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost. 2006 Oct;4(10):2140-7. doi: 10.1111/j.1538-7836.2006.02131.x. Epub 2006 Jul 17.
17 Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts. Biol Cell. 1997 Jul;89(4):295-307.
18 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
19 Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.
20 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Canadian Pharmacists Association.
23 Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT "Clopidogrel Markedly Increases the Plasma Concentrations of the CYP2C8 Substrate Pioglitazone." Drug Metab Dispos (2016):. [PMID: 27260150]
24 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
25 Clarke TA, Waskell LA "The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin." Drug Metab Dispos 31 (2003): 53-9. [PMID: 12485953]
26 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
27 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
28 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
29 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
32 Anand S, Yusuf S, Xie C, et al. "Oral anticoagulant and antiplatelet therapy and peripheral arterial disease." N Engl J Med 357 (2007): 217-27. [PMID: 17634457]
33 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
34 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
35 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
36 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
37 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
38 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
39 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
40 Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
41 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
42 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
43 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
44 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
46 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
47 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
48 Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther 67 (2000): 305-13. [PMID: 10741635]
49 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
50 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
51 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
52 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
53 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.
54 Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T "Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions." Br J Clin Pharmacol 49 (2000): 244-53. [PMID: 10718780]